Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EBITDA (2016 - 2025)

Lipocine (LPCN) has disclosed EBITDA for 13 consecutive years, with -$3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 44.64% year-over-year to -$3.2 million, compared with a TTM value of -$5.5 million through Sep 2025, down 35.94%, and an annual FY2024 reading of $10231.0, up 100.06% over the prior year.
  • EBITDA was -$3.2 million for Q3 2025 at Lipocine, down from -$2.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $12.6 million in Q4 2021 and bottomed at -$6.8 million in Q2 2021.
  • Average EBITDA over 5 years is -$1.8 million, with a median of -$2.6 million recorded in 2022.
  • The sharpest move saw EBITDA soared 379.48% in 2021, then crashed 176.93% in 2023.
  • Year by year, EBITDA stood at $12.6 million in 2021, then crashed by 117.24% to -$2.2 million in 2022, then fell by 4.01% to -$2.3 million in 2023, then soared by 178.8% to $1.8 million in 2024, then tumbled by 278.57% to -$3.2 million in 2025.
  • Business Quant data shows EBITDA for LPCN at -$3.2 million in Q3 2025, -$2.2 million in Q2 2025, and -$1.9 million in Q1 2025.